EXG102

EXG102 is an investigational gene therapy developed for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It utilizes a recombinant adeno-associated virus (rAAV) vector to deliver genetic material encoding a therapeutic fusion protein designed to bind and neutralize all known subtypes of vascular endothelial growth factor (VEGF-A, VEGF-B, VEGF-C, VEGF-D) and angiopoietin-2 (ANG2), key drivers of abnormal blood vessel formation and vascular leakage in the retina. The therapy is administered by subretinal injection. The approach aims to provide long-term suppression of neovascularization with a single administration by targeting multiple pathways involved in disease progression. Clinical trials are ongoing in the United States and China[1][2][3][4][5][6].